Lumos Diagnostics Holdings Ltd (ldx) Logo

Lumos Diagnostics Holdings Ltd (LDX)

___:___ · Healthcare

LDX Chart


LDX's Principal Activity is the development, manufacture and distribution of point-of-care diagnostic (POC) tests and associated readers for analysis of POC diagnostic tests.

Share Price Activity

Last (Price)
Change 0.00 (0.00)
Bid / Ask -
Volume (4w avg)
Day Range -
Prev Close
Last Trade


1 Week
1 Month
2022 YTD
1 Year
vs Sector (1yr) -
vs ASX 200 (1yr) -81.40%


Market Cap Question Mark Icon
Excludes mandatory escrowed shares and foreign shares.
ASX Rank 1,440 of 2,413
Sector Rank 123 of 210

Key Fundamentals

Shares Issued
Sector Healthcare
Similar Companies IDT / AGH / VBS
EPS $0.00
DPS $0.00
Book Value Per Share $0.00

Broker Consensus

LDX is not covered by a major broker, or data from most recent compilation was omitted due to not meeting QA guidelines.


Date Heading Pages File Size Time

Corporate Overview

Lumos Diagnostics Holdings Limited (LDX) is a developer and manufacturer of POC diagnostic tests. The company specializes in rapid, cost-effective and point-of-care (POC) diagnostic test solutions to help healthcare professionals more accurately diagnose and manage medical conditions and offers customized assay development and manufacturing services for POC tests and proprietary digital reader platforms.

Incorporation Details

No incorporation details available.

Corporate Details

Head Office South Melbourne VIC 3205
Registry Computershare
Auditor William Buck
Date Listed 5 Jul 2021

Upcoming Calendar (Forecasted)

Date Event
29/08/2022 Report (Prelim)
29/08/2022 Report (Annual)
27/02/2023 Report (Interim)

Dividend History

DPS and Yield calculations use the Pay Date.

Ex-Date Amount Franking Gross Type Payable
No dividends paid.

See Upcoming Dividends for all ASX companies.

Directors & Management

Directors & Management

Name Title Since Bio
Ms Catherine Robson Non-Executive Director Dec 2020

Ms Catherine Robson

Non-Executive Director

Ms Robson has more than 20 years' experience in management, finance and investment. Having commenced her career at Macquarie Bank, Catherine held senior roles at NAB before founding financial services business Affinity Private. Catherine is a non-executive director of ASX-listed EQT Holdings Limited, where she is the Chair of the risk committee and a member of the audit, remuneration and strategy committees. She is also a non-executive Director of Greater Bank and SCALE Investors and chairs education technology innovator TalkiPlay. Catherine is a member of WEHI's Advocacy & Support Committee and Cancer Council Victoria's Investment Committee. She is also Chair of the Risk Committee of LDX.

Ms Lawrence Mehren Non-Executive Deputy Chairman,Non-Executive Director Dec 2020

Ms Lawrence Mehren

Non-Executive Deputy Chairman,Non-Executive Director

Mr Mehren has over 20 years' experience working in the diagnostics industry, in both operational and financial roles. Between 2007 and 2012 Lawrence served as CFO and then COO of Ventana Medical Systems, a global supplier of cancer diagnostics systems which was acquired by Roche in 2008. In 2012 Lawrence assisted in the re-launch of Accelerate Diagnostics, a company dedicated to modernizing disease diagnostics, which went public on NASDAQ in 2012. Lawrence served as President, CEO and Director of the company from 2012 to January 2020. He is also member of the Risk Committee of LDX.

Ms Bronwyn Joyce Le Grice Non-Executive Director Nov 2020

Ms Bronwyn Joyce Le Grice

Non-Executive Director

Ms Le Grice has 20 years' experience in the technology and health technology sectors focused on commercialization, company growth, corporate development, investment and advocacy. Bronwyn previously served as a non-executive director for ASX listed Imagion BioSystems. Bronwyn is the founder and managing director of ANDHealth, an Australian dedicated digital health commercialisation organisation. Prior to founding ANDHealth, Bronwyn served as an Investment Director and Special Advisor for Bioscience Managers Pty Ltd, a healthcare fund manager and as Head of Commercial Development and Corporate Affairs for Adherium Ltd, including as project leader for their IPO in 2015. She is also member of the Risk Committee of LDX.

Mr Samuel Ross Garland Lanyon Executive Chairman,Executive Director,Interim Chief Executive Officer Dec 2018

Mr Samuel Ross Garland Lanyon

Executive Chairman,Executive Director,Interim Chief Executive Officer

Mr Lanyon has over 25 years' experience in business strategy, R&D and operational roles in the healthcare and technology markets. Sam co-founded and serves as co-CEO of Planet Innovation, a technology and commercialization company focused on global health-tech markets. Planet Innovation has assisted in the development/ creation of four standalone businesses (Lumos Diagnostics, Visus Therapeutics, Zen Ecosystems and Atomo Biosciences) since 2015. Sam previously served as an executive at ASX listed Vision Systems, where he was responsible for establishing and growing international commercial operations for its Vision Systems division until its acquisition by Danaher Corporation in 2007. Sam currently serves on the boards of Visus Therapeutics, Planet Innovation and Paragon Funds, and previously served on the boards of Zen Ecosystems and Waterwerx. He has undertaken governance training from the Australian Institute of Company Directors (AICD).

Ms Melanie Jaye Leydin Chief Financial Officer,Company Secretary N/A
Ms Tracy Weimar Company Secretary N/A

Director Transactions

LDX directors must report any change in shareholding to the ASX within 5 business days.

See Director Transactions for all ASX companies.

Date Director Type Amount Price Value Notes
28/10/21 Samuel Lanyon Issued 120,000 $1.25 $150,000 Issue of securities
28/10/21 Robert Sambursky Issued 24,000 $1.25 $30,000 Issue of securities

Director Interests

The current holdings of LDX directors.

Director Last Notice Direct Shares Indirect Shares Options Convertibles
Samuel Lanyon 28/10/2021 N/A 416,417 N/A N/A
Catherine Robson 26/12/2020 N/A 278,839 N/A N/A
Lawrence Mehren 16/12/2020 80,000 N/A N/A N/A
Bronwyn Le Grice 01/11/2020 N/A 28,400 N/A N/A

Shareholder Info

Top 20 Shareholders

Data supplied by Morningstar and accurate on Jun 29, 2021.

It's not possible to publish a real-time Top 20 Shareholder list. Companies are not obliged to report this data (with the exception of Substantial Shareholders above 5%). If a company chooses to publish the data, it's usually once a year in their Annual Report.

All data is manually compiled so there might be a delay between the Annual Report being published and the data appearing on Market Index (<7 days for ASX 300 and up to 30 days for micro-caps).

Name Shares Capital
Planet Innovation Holdings Limited 40,124,915 26.72%
RPS Diagnostics Inc 15,647,189 10.42%
National Nominees Limited 9,821,224 6.54%
BNP Paribas Nominees Pty Ltd (Drp) 6,573,877 4.38%
Washington H Soul Pattinson And Company Limited 4,177,990 2.78%
HSBC Custody Nominees (Australia) Limited 3,722,067 2.48%
Mainstream Fund Services Pty Ltd (Perennial P To P Opp A/C) (i) 3,544,737 2.36%
Citicorp Nominees Pty Limited 3,483,570 2.32%
BNP Paribas Noms Pty Ltd (Drp) 3,200,000 2.13%
Accbell Nominees Pty Ltd 2,957,601 1.97%
Mainstream Fund Services Pty Ltd (Perennial P To P Opp A/C) (ii) 2,900,239 1.93%
CS Third Nominees Pty Limited (HSBC Cust Nom Au Ltd 13 A/C) (i) 2,577,991 1.72%
Ellerston Capital Limited (Ellerston Pre Ipo A/C) 2,577,990 1.72%
Ellerston Capital Limited (Qpipo A/C) 2,577,990 1.72%
Brispot Nominees Pty Ltd (House Head Nominee A/C) 2,400,000 1.60%
UBS Nominees Pty Ltd 1,980,000 1.32%
CS Third Nominees Pty Limited (HSBC Cust Nom Au Ltd 13 A/C) (ii) 1,840,000 1.23%
HSBC Custody Nominees (Australia) Limited A/C 2 1,730,974 1.15%
Bell Potter Nominees Ltd (Bb Nominees A/C) 1,680,000 1.12%
HSBC Custody Nominees (Australia) Limited-Gsco Eca 1,600,000 1.07%

Shareholder Distribution

As reported in the most recent Annual Report.

Holding Size 1 - 1,000 1,001 - 5,000 5,001 - 10,000 10,001 - 100,000 100,001+ Total
No. of Shareholders 9 373 297 378 80 1,137

Substantial Shareholders

No Substantial Shareholders for LDX in our database.

Shareholders Buying

12 month transaction history compiled from ASX announcements.

Date Name Bought Previous % New %
10-03-22 Perennial Value Management Limited 1,732,244 11.52 12.64
23-12-21 Perennial Value Management Limited 1,990,405 10.21 11.52
16-09-21 Perennial Value Management Limited 1,614,847 9.14 10.21
30-07-21 Perennial Value Management Limited 1,988,790 7.81 9.14
06-07-21 Acorn Capital Limited 8,973,877 -- 5.98
05-07-21 Ellerston Capital Limited 8,155,980 -- 5.43

Shareholders Selling

12 month transaction history compiled from ASX announcements.

Date Name Sold Previous % New %
17-12-21 Ellerston Capital Limited 8,155,980 5.43 --

Historical Data

Share Price History

Date Close Change %Chg Open High Low Volume Turnover

Historical Data

Year Closing Price Last Trade
No Financial Year End data available
LDX Historical Price Data (CSV)
Up to 20 years of EOD share price history
You must be logged in to access this feature. Please sign up for free or login.
Market Index, ASX and Morningstar Logos

All data on this page is supplied by the ASX, Morningstar and Market Index. Read the disclaimer.